Skip to main content
SpringerLink
Log in

Serum α-l-fucosidase

A more sensitive marker for hepatocellular carcinoma?

  • Conference Report
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Forty-nine liver disease patients (7 chronic persistent hepatitis, CPH; 10 chronic active hepatitis, CAH; 13 liver cirrhosis, LC; 9 primary hepatocellular carcinoma, PHC, without LC; and 10 PHC with associated LC) and 20 controls were assessed for their serum α-l-fucosidase (ALF) and α-fetoprotein (AFP) levels and several routine liver injury parameters. Tumor diameter in those with hepatic cancer was assessed by angio-CT. Only ALF and AFP were significantly greater in patients with PHC and PHC+LC patients as compared to patients with LC alone. At an accepted cutoff level of 500 ng/ml, the AFP level provided 43% false negative tests. On the other hand, an ALF level exceeding 740 μmol/hr/ml provided a sensitivity of 84% with a specificity of 94%. No relationship between the ALF level and Child's criteria or with any liver injury parameter was evident. Considering all individual values, the ALF, rather than the AFP, correlated with tumor size. This finding suggests the ALF level may be of value in the early detection of PHC as well as in the follow-up of patients treated for PHC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Beasley RP, Lin CC, Hwang LY, Chien CS: Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 2:1129–1133, 1981

    Google Scholar 

  2. Kubo Y, Okuda K, Musha H, Nakashima T: Detection of hepatocellular carcinoma during a clinical follow-up of chronic liver disease. Gastroenterology 74:578–582, 1978

    Google Scholar 

  3. Heyward WL, Lanier AP, Bender TR, Mc Mahon BJ, Kilkenny S, Paprocki TR, Kline KT, Silimperi DR, Maynard JE: Early detection of prymary hepatocellular carcinoma by screening for α-fetoprotein in high risk families: A case report. Lancet 2:1161–1162, 1983

    Google Scholar 

  4. Oberfield RA, Templeton AC, Williams L: Cancer of the liver. Cancer Manual. American Cancer Society, Massachusetts Division, 1982

  5. Sawabu N, Hattori N: Serological tumor markers in hepatocellular carcinoma.In Neoplasms of the liver. K Okuda, M Kojiro (eds). Tokyo, Springer-Verlag, 1987, pp 227–238

    Google Scholar 

  6. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, Hsu HC, Chuang CN, Yang PC, Wang TH, Lin JC, Lee CZ: Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 89:259–266, 1985

    Google Scholar 

  7. Matsumoto Y, Suzuki T, Asada I, Ozawa K, Tobe K, Honjio I: Clinical classification of hepatoma in Japan according to serial changes of serum α-feto-protein levels. Cancer 49:354–359, 1982

    Google Scholar 

  8. Deugnier Y, David V, Brissot P, Mabo P, Delamare D, Messner M, Bourel M, Legal JY: Serum α-l-fucosidase: A new marker for the diagnosis of prymary hepatic carcinoma? Hepatology 4:889–892, 1984

    Google Scholar 

  9. International Group. Acute and chronic hepatitis revisited. Lancet 2:914–919, 1977

    Google Scholar 

  10. Child CG, Turcotte JG: Surgery and portal hypertension.In The Liver and Portal Hypertension. CG Child (ed). Philadelphia, WB Saunders, 1964, p 50

    Google Scholar 

  11. Zielke K, Okada S, O'Brien JS: Fucosidosis: Diagnosis by serum assay of α-l-fucosidase. J Lab Clin Med 79:164–169, 1972

    Google Scholar 

  12. Reglero A, Carretero MI, Cabezas JA: Increased serum α-l-fucosidase and β-N-acetylglucosaminidase activities in diabetic, cirrhotic and gastric cancer patients. Clin Chim Acta 103:155–158, 1980

    Google Scholar 

  13. Deugnier Y, Le Treut A, Glaise D, Brissot P, Le Galle JY: A study of lysosomal enzyme activities in serum and leukocytes in chronic liver diseases. Clin Chim Acta 108:385–392, 1980

    Google Scholar 

  14. Leray G, Deugnier Y, Jouanolle AM, Lehry D, Bretagne JF, Campion JP, Brissot P, Le Treut A: Biochemical aspects of α-l-fucosidase in hepatocellular carcinoma. Hepatology 9:249–252, 1989

    Google Scholar 

  15. Tang ZY, Yu YQ, Lin ZY: Subclinical hepatocellular carcinoma. Chin J Oncol 5:226–228, 1983

    Google Scholar 

  16. Zang ZY, Yu YQ, Zhou YD: Research on Small Hepatocellular Carcinoma. Beijing, Chinese Science and Technical Literature Publishers, 1982, pp 7–11

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Econum Laboratory, Université des Sciences et Techniques de Lille, France

    Francesco Marotta MD, PhD, Hua De Chui MD, PhD, Patrick Safran, D. Biol & Shu Chin Zhang MD

  2. Department of Internal Medicine, Norman Bethune University of Sciences, Changchun, China

    Francesco Marotta MD, PhD, Hua De Chui MD, PhD, Patrick Safran, D. Biol & Shu Chin Zhang MD

Authors
  1. Francesco Marotta MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hua De Chui MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick Safran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Biol
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shu Chin Zhang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marotta, F., De Chui, H., Safran, P. et al. Serum α-l-fucosidase. Digest Dis Sci 36, 993–997 (1991). https://doi.org/10.1007/BF01297154

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01297154

Key Words

Search

Navigation